医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japanese CRO CAC EXICARE Teams with Medidata to Improve Customers’ Clinical Trial Efficiency and Effectiveness Through Cloud Technology

2013年04月16日 PM09:55
このエントリーをはてなブックマークに追加


 

NEW YORK & TOKYO

Japan-based contract research organization (CRO) CAC EXICARE has joined Medidata Solutions’ (NASDAQ: MDSO) Partner Program to expand its services offerings to support the Medidata Clinical Cloud™. As a new Medidata Services Partner, CAC EXICARE is pursuing several accreditations across the Medidata cloud-based platform to support clinical trials in all phases, including Japanese post-marketing surveillance studies. Medidata’s innovative solutions for randomization and trial supply management (RTSM), electronic data capture and management, and medical coding will be supported by CAC EXICARE.

CAC EXICARE is a 2012 spinoff from CAC, an extensive IT services organization that has been supporting operations of pharmaceutical companies for more than 40 years. With deep expertise applying technology to bring efficiencies to its customer base of more than 150 life science companies, including Japanese branches of global pharmaceutical corporations, CAC EXICARE supports all phases of clinical development. At the request of many of their customers, CAC EXICARE decided to become a Medidata Services Partner and pursue accreditation in Medidata Rave®, the leading electronic data capture (EDC) and clinical data management (CDM) system, and is also pursuing accreditations in Medidata Balance® (for RTSM) and Medidata Coder® (for medical coding).

  • “We are excited to partner with Medidata Solutions to further strengthen our service offerings that bring efficiencies and effectiveness to clinical trials,” said Koji Iwamoto, business development and planning deputy manager, CAC EXICARE. “Our customers have seen the benefits of Medidata Rave, including improved site productivity, data access and workflow, and anticipate the optimization advantages of the broader Medidata Clinical Cloud.”

The nature of clinical research demands solutions that are globally accessible and still meet regulatory and security requirements. Medidata’s standards-based platform provides CAC EXICARE with a secure, collaborative environment that is configurable and flexible, —including easily integrating with other systems—accelerates study start-ups and enhances study execution.

  • “With their commitment to bringing technology-based advantages to life science organizations, CAC EXICARE shares our vision to accelerate and enhance clinical trial management and decision making through technology,” said Steve Heath, vice president of channel sales at Medidata Solutions. “We are delighted to welcome CAC EXICARE as a Medidata Services Partner to help us serve the APAC region’s increasing demand for the Medidata Clinical Cloud, and we are confident that their customers will derive value from it quickly.”

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer implementation services for Medidata Rave. Since then, the Medidata Partner Program has grown to include 38 partners in the U.S., Europe and Asia, ranging from smaller clinical consultancies to large, global CROs. The program also now offers eight accreditations across the Medidata platform and supports partners with a variety of on-demand resources to help them optimize sponsors’ clinical trials.

Connect with Medidata:

About CAC EXICARE

CAC EXICARE is an IT systems integrator with rich experience and knowledge related to pharmaceutical R&D, as well as a CRO that provides contract services from clinical development to post-marketing surveillance. In April 2012, CAC Corporation split off its business unit of the clinical development operation and IT support services, and the new spinoff company started its business as CAC EXICARE Corporation. For more than past 40 years, we have been supporting operations of pharmaceutical companies by leveraging IT competence as our foundation.

About Medidata Solutions

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

CONTACT

Edelman
Geoff Curtis
+1 312 233 1253
Geoff.Curtis@edelman.com
or
CAC
EXICARE
Hiroshi Watanabe
BTO Business Planning Office
Corporate
Planning Dept.
+81 3 6667 8032
hirowata@cac.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗